Literature DB >> 15059905

Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint.

Tamotsu Sudo1, Masayuki Nitta, Hideyuki Saya, Naoto T Ueno.   

Abstract

Paclitaxel stabilizes microtubules, causing mitotic arrest and activating the spindle assembly checkpoint. We determined whether suppression of the checkpoint genes Mad2 and BubR1 affects paclitaxel resistance and whether overexpression of Mad2 protein in checkpoint-defective cells enhances paclitaxel sensitivity. Suppression of Mad2 and BubR1 in paclitaxel-treated cancer cells abolished checkpoint function, resulting in paclitaxel resistance that correlated with suppression of cyclin-dependent kinase-1 activity. In contrast, overexpression of Mad2 in cells with a checkpoint defect attributable to low Mad2 expression restored checkpoint function, resulting in enhanced paclitaxel sensitivity that correlated with enhanced cyclin-dependent kinase-1 activity. However, overexpression of Mad2 failed to enhance paclitaxel sensitivity via checkpoint activation in Mad2-independent checkpoint-defective and -intact cells. Thus, checkpoint function is required for paclitaxel sensitivity. These findings show that any molecules that could interfere with the spindle assembly checkpoint could generate paclitaxel resistance in any patient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059905     DOI: 10.1158/0008-5472.can-03-2013

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  87 in total

Review 1.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

2.  Up-regulation of the mitotic checkpoint component Mad1 causes chromosomal instability and resistance to microtubule poisons.

Authors:  Sean D Ryan; Eric M C Britigan; Lauren M Zasadil; Kristen Witte; Anjon Audhya; Avtar Roopra; Beth A Weaver
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

Review 3.  Spindle checkpoint function and cellular sensitivity to antimitotic drugs.

Authors:  Hiroshi Y Yamada; Gary J Gorbsky
Journal:  Mol Cancer Ther       Date:  2006-12       Impact factor: 6.261

4.  Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.

Authors:  Aina He; Weixiang Qi; Yujing Huang; Yuanjue Sun; Zan Shen; Hui Zhao; Yumei Yang; Yang Yao
Journal:  Int J Clin Oncol       Date:  2012-04-26       Impact factor: 3.402

Review 5.  DNA repair and personalized breast cancer therapy.

Authors:  Shu-Xia Li; Ashley Sjolund; Lyndsay Harris; Joann B Sweasy
Journal:  Environ Mol Mutagen       Date:  2010 Oct-Dec       Impact factor: 3.216

6.  BubR1 deficiency results in enhanced activation of MEK and ERKs upon microtubule stresses.

Authors:  Y L Yang; Q Duan; T B Guo; X X Wang; Q Ruan; G T Xu; J W Zhang; Z Y Lu; M Xu; L Lu; W Dai
Journal:  Cell Prolif       Date:  2007-06       Impact factor: 6.831

7.  Intracellular proadrenomedullin-derived peptides decorate the microtubules and contribute to cytoskeleton function.

Authors:  Dan L Sackett; Laurent Ozbun; Enrique Zudaire; Lisa Wessner; John M Chirgwin; Frank Cuttitta; Alfredo Martínez
Journal:  Endocrinology       Date:  2008-03-06       Impact factor: 4.736

8.  Constitutive Cdk2 activity promotes aneuploidy while altering the spindle assembly and tetraploidy checkpoints.

Authors:  Stephan C Jahn; Patrick E Corsino; Bradley J Davis; Mary E Law; Peter Nørgaard; Brian K Law
Journal:  J Cell Sci       Date:  2013-01-15       Impact factor: 5.285

9.  Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells.

Authors:  J Bargiela-Iparraguirre; L Prado-Marchal; N Pajuelo-Lozano; B Jiménez; R Perona; I Sánchez-Pérez
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 10.  Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?

Authors:  J Thomas De Ligio; Aneliya Velkova; Diego A R Zorio; Alvaro N A Monteiro
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.